Chinese Journal Of Clinical Anatomy ›› 2014, Vol. 32 ›› Issue (6): 698-703.doi: 10.13418/j.issn.1001-165x.201

Previous Articles     Next Articles

Experimental study on the influence of P38MAPK inhibitor SB202190 on cytokines in flap ischemic reperfusion injury

WU Jian-long,JU Ji-hui,ZHOU Guang-liang,JIN Guang-zhe,LI Zhi-min,HOU Rui-xing   

  1. Department of Hand Surgery, Ruihua Affiliated Hospital of Soochow University, Suzhou, 215104,  China
  • Received:2014-08-11 Online:2014-11-25 Published:2014-12-04

Abstract:

Objective To explore the P38 MAPK inhibitor SB202190 on IRI development and TNF-α、IL-10 expression levels in flap.  Methods    Forty-eight Wistar rats aged 12~14 weeks old, were randomly divided into control group (groupⅠ), ischemia-reperfusion group (groupⅡ), saline group (groupⅢ), P38 MAPK inhibitor group (groupⅣ). The superficial epigastric artery flap ischemia reperfusion injury model was made in the left lower quadrant abdominal of each rat. The flaps were harvested 7 days after injection to receive immunohistochemistry observation, and P38MAPK、P-P38MAPK scoring. The TNF-α and IL-10 levels of the superficial epigastric vein were tested.    Results    The survival rates of the flaps 7 days after operation in group Ⅳ was higher than in group Ⅱand Ⅲ significantly(P<0.05). The expression of P38MAPK and P-P38MAPK in groupⅣ was lower than that in groupⅡand Ⅲ. The expression of TNF-α in groupⅣ was lower than that in groupⅡand Ⅲ,but the IL-10 content in groupⅣ was higher than that in groupⅡ and Ⅲ. Pearson correlation analysis showed that there was a significant negative correlation between flap survival rates and TNF-α level; there was a significant positive correlation between P38MAPK, P-P38MAPK scoring and TNF-α level.  Conclusion   The intraperitoneal use of P38 MAPK inhibitor SB202190 can decrease of the plasma TNF-α level, and improve skin flap survival from the Ischemia- reperfusion injury by preventing the activation of P38MAPK pathway

Key words: Flap, Ischemia-reperfusion, SB202190, TNF-α

CLC Number: